To explore the characteristics of intestinal flora in patients with chronic liver disease based on 16S rDNA gene sequencing technology

Abstract

Abstract: Objective By comparing the intestinal flora characteristics of different chronic liver disease patients and healthy volunteers, the differences and associations of intestinal flora between chronic liver disease patients and healthy volunteers were explored. Methods A total of 60 patients with chronic liver disease (including 16 patients with chronic hepatitis B, 37 patients with cirrhosis, and 7 patients with hepatocellular carcinoma) and 37 healthy volunteers were selected from the Third People's Hospital of Yunnan Province from February 2023 to August 2023.Fresh fecal samples were collected, DNA was extracted and 16S rDNA high-throughput sequencing technology was used to detect intestinal flora, and microbial diversity and composition were analyzed. Results In terms of alpha diversity, compared with the healthy control group, the intestinal flora richness and diversity of patients in each chronic liver disease group were significantly reduced, and the flora richness and diversity continued to decline during the progression of chronic hepatitis B→cirrhosis→hepatocellular carcinoma. In terms of species abundance, with the progression of chronic hepatitis B→cirrhosis→hepatocellular carcinoma, the abundance of Escherlchia-Shigella increased continuously.Among the distinct species screened at the generic level, compared to healthy controls, Faecalibacterium, Agathobacter, Prevotella-9, Dialister, Roseburia and Ruminococcus in each chronic liver disease groupThe relative abundance of eight bacteria genera, including Coprococcus and Subdoligranulum, decreased.LEfSe analysis showed that intestinal dominant bacterium was different in different stages of chronic liver disease. Conclusion Patients with chronic liver disease have significantly different intestinal flora characteristics compared with healthy controls, and changes in the abundance of Escherlchia-Shigella may mediate the progression of chronic hepatitis B→cirrhosis→hepatocellular carcinoma. And with the progression of chronic hepatitis B→cirrhosis→hepatocellular carcinoma disease, the intestinal dominant bacterium is also changing.

Key words: Chronic liver disease, Intestinal flora, 16S rDNA sequencing, Diversity analysis, Differential species analysis

MA Chi, YANG Juan, ZHANG Sheng, FU Xin-nian, LUO Jiang-yan, WANG Xin-xin, MA Xiao-ying, MAO Xiao-zhou. To explore the characteristics of intestinal flora in patients with chronic liver disease based on 16S rDNA gene sequencing technology[J]. Chinese Hepatolgy, 2025, 30(5): 683-689.

References

[1] Moon A M, Singal A G, Tapper EB. Contemporary epidemiology of chronic liver disease and cirrhosis[J]. Clin Gastroenterol Hepatol,2020,18(12):2650-2666.
[2] Paik J M, Golabi P, Younossi Y, et al. Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD[J]. Hepatology, 2020,72(5):1605-1616.
[3] 中华医学会肝病学分会.慢性乙型肝炎防治指南(2022年版)[J].中华肝脏病杂志,2022,12:1309-1331.
[4] 中华医学会肝病学分会.肝硬化诊治指南(2019年版)[J].中华肝脏病杂志,2019,11:846-865.
[5] 中华医学会肝病学分会.原发性肝癌诊治指南(2022年版)[J].中华肝脏病杂志,2022,4:367-388.
[6] Kassa Y, Million Y, Gedefie A, et al. Alteration of gut microbiota and its impact on immune response in patients with chronic HBV infection: a review[J]. Infect Drug Resist,2021,14:2571-2578.
[7] Liu L, Zhang C, Hu Y, et al. Changes in gut toll-like receptor-4 and nod-like receptor family pyrin domain containing-3 innate pathways in liver cirrhosis rats with bacterial translocation[J]. Clin Res Hepatol Gastroenterol,2016,40(5):575-583.
[8] Sun X, Pan C Q, Xing H. Effect of microbiota metabolites on the progression of chronic hepatitis B virus infection[J]. Hepatol Int, 2021,15(5):1053-1067.
[9] Litwinowicz K, Gamian A. Microbiome alterations in alcohol use disorder and alcoholic liver disease[J]. Int J Mol Sci,2023,24(3):2461.
[10] Hu C, Xu B, Wang X, et al. Gut microbiota-derived short-chain fatty acids regulate group 3 innate lymphoid cells in HCC[J]. Hepatology,2023,77(1):48-64.
[11] Mohamed Elfadil O, Mundi M S, Abdelmagid M G, et al. Butyrate: more than a short chain fatty acid[J]. Curr Nutr Rep,2023,12(2):255-262.
[12] Singh V, Lee G, Son H, et al. Butyrate producers, "the sentinel of gut": their intestinal significance with and beyond butyrate, and prospective use as microbial therapeutics[J]. Front Microbiol,2023,13:1103836.
[13] Seo B, Jeon K, Moon S, et al. Roseburia spp. Abundance associates with alcohol consumption in humans and its administration ameliorates alcoholic fatty liver in mice[J]. Cell Host Microbe,2020,27(1):25-40.
[14] Gurav A, Sivaprakasam S, Bhutia Y D, et al. Slc5a8, a Na⁺-coupled high-affinity transporter for short-chain fatty acids, is a conditional tumour suppressor in colon that protects against colitis and colon cancer under low-fibre dietary conditions[J]. Biochem J,2015,469(2):267-278.
[15] Li H B, Xu M L, Xu X D, et al. Faecalibacterium prausnitzii attenuates CKD via butyrate-renal GPR43 axis[J]. Circ Res,2022,131(9):e120-e134.
[16] Martín R, Rios-covian D, Huillet E, et al. Faecalibacterium: a bacterial genus with promising human health applications[J]. FEMS Microbiol Rev,2023,47(4):fuad039.
[17] Xu W, Jiang Y, Tao J, et al. Correlation analysis for alterations of intestinal flora in hepatocellular carcinoma patients: combinatorial detection of coriobacterium, atopobium, coprococcus and veillonella dispar may be a new method for HCC diagnosis[J]. J Med Microbiol,2023,72(6):10.1099/jmm.0.001713.
[18] Zhao J, Bai M, Ning X, et al. Expansion of escherichia-shigella in gut is associated with the onset and response to immunosuppressive therapy of IgA nephropathy[J]. J Am Soc Nephrol,2022,33(12):2276-2292.
[19] Yang L, Xiang Z, Zou J, et al. Comprehensive analysis of the relationships between the gut microbiota and fecal metabolome in individuals with primary sjogren′s syndrome by 16S rRNA sequencing and LC-MS-based metabolomics[J]. Front Immunol,2022,13:874021.
[20] Collazos J. Glycocholic acid in chronic active hepatitis and mild liver diseases[J]. Clin Investig,1993,72(1):36-39.
[21] Yuan Z, Wang J, Zhang H, et al. Glycocholic acid aggravates liver fibrosis by promoting the up-regulation of connective tissue growth factor in hepatocytes[J]. Cell Signal,2023,101:110508.